<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032629</url>
  </required_header>
  <id_info>
    <org_study_id>CR016627</org_study_id>
    <secondary_id>28431754DIA3008</secondary_id>
    <secondary_id>2009-012140-16</secondary_id>
    <nct_id>NCT01032629</nct_id>
  </id_info>
  <brief_title>CANVAS - CANagliflozin cardioVascular Assessment Study</brief_title>
  <acronym>CANVAS</acronym>
  <official_title>A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The George Institute for Global Health, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2
      diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac
      events (MACE). Other objectives include evaluating the overall safety, tolerability, and
      effectiveness of canagliflozin.

      The data from this study will be combined with the data from CANVAS-R study (Study of the
      Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a
      pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing
      requirements for canagliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate canagliflozin compared to placebo on CV events including CV death,
      heart attack, and stroke in patients with T2DM, whose diabetes is not well controlled at the
      beginning of the study and who have a history of CV events or have a high risk for CV events.
      The study includes 3 substudies which will compare the effectiveness of lowering blood
      glucose and assess the safety of canagliflozin relative to placebo in patients receiving
      specific commonly-used diabetes agents. 4,330 participants will be randomly assigned to
      treatment with 1 of 2 doses of canagliflozin (100 or 300 mg) or placebo, in a 1:1:1 ratio.
      This study was originally designed to last for up to 9 years. As per FDA post-marketing
      requirements for canagliflozin, the study's last subject last visit will now occur when
      enough MACE events (ie, CV death, nonfatal myocardial infarction, nonfatal stroke) are
      accumulated between the CANVAS (this study) and CANVAS-R studies. The completion target was
      reached in February 2017.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 9, 2009</start_date>
  <completion_date type="Actual">February 22, 2017</completion_date>
  <primary_completion_date type="Actual">February 22, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke</measure>
    <time_frame>Up to approximately 8 years</time_frame>
    <description>MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Progression of Albuminuria at the End-of-Treatment</measure>
    <time_frame>End of treatment (approximately 338 weeks)</time_frame>
    <description>Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [&gt;=] 30 milligram per gram (mg/g) and less than or equal to &lt;= 300 mg/g) or macroalbuminuria (ACR of &gt;300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment</measure>
    <time_frame>Baseline and End of treatment (approximately 338 weeks)</time_frame>
    <description>Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Percent change from baseline in body weight was assessed at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in systolic blood pressure and diastolic blood pressure was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides Levels at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in triglycerides levels was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment</measure>
    <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
    <description>Change from baseline in LDL-C to HDL-C ratio was assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4330</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Risk Factors</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin (JNJ-28431754) 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin (JNJ-28431754) 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One placebo capsule taken orally (by mouth) once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin (JNJ-28431754) 100 mg</intervention_name>
    <description>One 100 mg capsule taken orally (by mouth) once daily</description>
    <arm_group_label>Canagliflozin (JNJ-28431754) 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin (JNJ-28431754) 300 mg</intervention_name>
    <description>One 300 mg capsule taken orally (by mouth) once daily</description>
    <arm_group_label>Canagliflozin (JNJ-28431754) 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a diagnosis of type 2 diabetes mellitus and greater than or equal
             to (&gt;=) 30 yrs old with history of cardiovascular (CV) event, or &gt;= 50 yrs old with
             high risk of CV events

          -  Patients must have inadequate diabetes control (as defined by glycosylated hemoglobin
             greater than or equal to 7.0% to less than or equal to 10.5% at screening) and be
             either (1) not currently on diabetes drug therapy or (2) on therapy with any approved
             class of diabetes drugs

        Exclusion Criteria:

          -  A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell
             transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  History of one or more severe hypoglycemic (ie, very low blood sugar) episode within 6
             months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma De Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Godoy Cruz</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar Del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auchenflower</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caboolture</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caringbah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daw Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Ringwood</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth Vale</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hornsby, Nsw 2077</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kippa Ring</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Launceston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reservoir</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherwood</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Leonards</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlon</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nemarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Val-Belair</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kralupy Nad Vltavou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moravsky Krumlov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc 9</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisek</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 11</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Znojmo N/A</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viljandi</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nimes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pirna</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saarlouis</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Speyer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mosonmagyaróvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahemadabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ambawadi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore, Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calicut</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ernakulam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ghaziabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patna</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rajkot</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trivandrum, Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vadodhara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vijayawada</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Visakhapatnam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Georgetown</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur N/A</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petaling Jaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Subang Jaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Celaya</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Helder</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoorn Nh</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Velp Gld</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwijndrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bekkestua</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lierskogen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skedsmokorset</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciechocinek</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gniewkowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grudziadz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slawkow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov-On-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Russia</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl Nap</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almeria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Figueres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan De Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla N/A</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viladecans</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oskarshamn N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piteå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ternopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Londonderry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randalstown</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Luxembourg</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <results_first_submitted>August 24, 2018</results_first_submitted>
  <results_first_submitted_qc>November 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2018</results_first_posted>
  <disposition_first_submitted>February 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 20, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 22, 2018</disposition_first_posted>
  <last_update_submitted>November 5, 2018</last_update_submitted>
  <last_update_submitted_qc>November 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Cardiovascular outcomes</keyword>
  <keyword>Canagliflozin (JNJ-28431754)</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01032629/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01032629/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No Text enterred</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 100 mg</title>
          <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="P3">
          <title>Canagliflozin 300 mg</title>
          <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1442"/>
                <participants group_id="P2" count="1445"/>
                <participants group_id="P3" count="1443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="1441"/>
                <participants group_id="P2" count="1445"/>
                <participants group_id="P3" count="1441"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1297">Participants who died on trial were considered completed</participants>
                <participants group_id="P2" count="1344">Participants who died on trial were considered completed</participants>
                <participants group_id="P3" count="1355">Participants who died on trial were considered completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Closed Site</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 100 mg</title>
          <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="B3">
          <title>Canagliflozin 300 mg</title>
          <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1442"/>
            <count group_id="B2" value="1445"/>
            <count group_id="B3" value="1443"/>
            <count group_id="B4" value="4330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="7.94"/>
                    <measurement group_id="B2" value="62.2" spread="8"/>
                    <measurement group_id="B3" value="62.8" spread="8.13"/>
                    <measurement group_id="B4" value="62.4" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="486"/>
                    <measurement group_id="B2" value="484"/>
                    <measurement group_id="B3" value="499"/>
                    <measurement group_id="B4" value="1469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="956"/>
                    <measurement group_id="B2" value="961"/>
                    <measurement group_id="B3" value="944"/>
                    <measurement group_id="B4" value="2861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="416"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1288"/>
                    <measurement group_id="B2" value="1300"/>
                    <measurement group_id="B3" value="1317"/>
                    <measurement group_id="B4" value="3905"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="263"/>
                    <measurement group_id="B4" value="795"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1064"/>
                    <measurement group_id="B2" value="1060"/>
                    <measurement group_id="B3" value="1055"/>
                    <measurement group_id="B4" value="3179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="263"/>
                    <measurement group_id="B4" value="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Non- Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="929"/>
                    <measurement group_id="B2" value="934"/>
                    <measurement group_id="B3" value="948"/>
                    <measurement group_id="B4" value="2811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luxembourg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="249"/>
                    <measurement group_id="B4" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke</title>
        <description>MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.</description>
        <time_frame>Up to approximately 8 years</time_frame>
        <population>The primary analysis was based on the intent-to-treat (ITT) analysis set for adjudicated MACE, and included all randomized participants. As per planned analysis, the results were reported separately and combined for both doses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin (Total)</title>
            <description>Participants received one canagliflozin 100 mg or 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke</title>
          <description>MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.</description>
          <population>The primary analysis was based on the intent-to-treat (ITT) analysis set for adjudicated MACE, and included all randomized participants. As per planned analysis, the results were reported separately and combined for both doses.</population>
          <units>Events per 1000 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1442"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="1443"/>
                <count group_id="O4" value="2888"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.36"/>
                    <measurement group_id="O2" value="28.41"/>
                    <measurement group_id="O3" value="25.37"/>
                    <measurement group_id="O4" value="26.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.4576</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0467</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1120</p_value>
            <method>Cox proportional hazard method</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)</title>
        <description>The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) included subset of participants who were not receiving insulin at baseline and had at least one post-baseline HOMA2-%B measurement on-treatment prior to initiation of insulin.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)</title>
          <description>The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) included subset of participants who were not receiving insulin at baseline and had at least one post-baseline HOMA2-%B measurement on-treatment prior to initiation of insulin.</population>
          <units>Percentage of HOMA2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="511"/>
                <count group_id="O3" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="1.611"/>
                    <measurement group_id="O2" value="6.82" spread="1.533"/>
                    <measurement group_id="O3" value="8.09" spread="1.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.210</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>2.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.224</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.571</ci_lower_limit>
            <ci_upper_limit>7.154</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.072</p_value>
            <method>ANCOVA</method>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>4.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.261</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.368</ci_lower_limit>
            <ci_upper_limit>8.504</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Progression of Albuminuria at the End-of-Treatment</title>
        <description>Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [&gt;=] 30 milligram per gram (mg/g) and less than or equal to &lt;= 300 mg/g) or macroalbuminuria (ACR of &gt;300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed.</description>
        <time_frame>End of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were treated, had both baseline and post−baseline ACR measurements, and baseline ACR&lt;=300 mg/g.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Progression of Albuminuria at the End-of-Treatment</title>
          <description>Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to [&gt;=] 30 milligram per gram (mg/g) and less than or equal to &lt;= 300 mg/g) or macroalbuminuria (ACR of &gt;300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were treated, had both baseline and post−baseline ACR measurements, and baseline ACR&lt;=300 mg/g.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1286"/>
                <count group_id="O2" value="1334"/>
                <count group_id="O3" value="1298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment</title>
        <description>A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set: all randomized participants who received at least 1 dose of study drug. 'N' (number of participants analyzed): number of participants evaluable for this outcome measure, had both baseline and any post-baseline PI/I ratio measurements on-treatment prior to initiation of insulin and didn’t receive insulin through baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment</title>
          <description>A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion.</description>
          <population>On-treatment analysis set: all randomized participants who received at least 1 dose of study drug. 'N' (number of participants analyzed): number of participants evaluable for this outcome measure, had both baseline and any post-baseline PI/I ratio measurements on-treatment prior to initiation of insulin and didn’t receive insulin through baseline.</population>
          <units>Picomole per milli international units</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.150"/>
                    <measurement group_id="O2" value="0.67" spread="0.140"/>
                    <measurement group_id="O3" value="1.03" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.205</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.429</ci_lower_limit>
            <ci_upper_limit>0.374</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.206</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.079</ci_lower_limit>
            <ci_upper_limit>0.731</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment</title>
        <description>Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine.</description>
        <time_frame>Baseline and End of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and had both baseline and post-baseline ACR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment</title>
          <description>Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and had both baseline and post-baseline ACR measurements.</population>
          <units>Milligram per gram (mg/g)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1377"/>
                <count group_id="O2" value="1398"/>
                <count group_id="O3" value="1384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.30" lower_limit="27.66" upper_limit="31.03"/>
                    <measurement group_id="O2" value="25.50" lower_limit="24.09" upper_limit="27"/>
                    <measurement group_id="O3" value="24.47" lower_limit="23.11" upper_limit="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.800</ci_lower_limit>
            <ci_upper_limit>0.940</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.770</ci_lower_limit>
            <ci_upper_limit>0.910</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment</title>
        <description>Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black).</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure who had both baseline and post-baseline eGFR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment</title>
          <description>Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m^2) = 175 * (serum creatinine) ^ 1.154 * (Age) ^-0.203 *(0.742 if female) * (1.21 if Black).</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure who had both baseline and post-baseline eGFR measurements.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1394"/>
                <count group_id="O2" value="1412"/>
                <count group_id="O3" value="1383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.23" spread="0.390"/>
                    <measurement group_id="O2" value="-3.55" spread="0.388"/>
                    <measurement group_id="O3" value="-3.98" spread="0.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>1.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.550</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.599</ci_lower_limit>
            <ci_upper_limit>2.755</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>1.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.553</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.160</ci_lower_limit>
            <ci_upper_limit>2.328</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment</title>
        <description>Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure who had both baseline and any post-baseline HbA1C measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment</title>
          <description>Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure who had both baseline and any post-baseline HbA1C measurements.</population>
          <units>HbA1c (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1366"/>
                <count group_id="O2" value="1392"/>
                <count group_id="O3" value="1352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.032"/>
                    <measurement group_id="O2" value="-0.26" spread="0.032"/>
                    <measurement group_id="O3" value="-0.31" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.355</ci_lower_limit>
            <ci_upper_limit>-0.177</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.405</ci_lower_limit>
            <ci_upper_limit>-0.227</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment</title>
        <description>Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and had both baseline and post-baseline fasting plasma glucose measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment</title>
          <description>Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and had both baseline and post-baseline fasting plasma glucose measurements.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1392"/>
                <count group_id="O2" value="1410"/>
                <count group_id="O3" value="1377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.076"/>
                    <measurement group_id="O2" value="-0.42" spread="0.075"/>
                    <measurement group_id="O3" value="-0.57" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.794</ci_lower_limit>
            <ci_upper_limit>-0.374</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.108</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.945</ci_lower_limit>
            <ci_upper_limit>-0.523</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight at End-of-Treatment</title>
        <description>Percent change from baseline in body weight was assessed at the end of treatment.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline body weight.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at End-of-Treatment</title>
          <description>Percent change from baseline in body weight was assessed at the end of treatment.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline body weight.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1398"/>
                <count group_id="O2" value="1415"/>
                <count group_id="O3" value="1388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.184"/>
                    <measurement group_id="O2" value="-3.47" spread="0.183"/>
                    <measurement group_id="O3" value="-4.12" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-2.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.260</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.472</ci_lower_limit>
            <ci_upper_limit>-2.454</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-3.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.261</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.125</ci_lower_limit>
            <ci_upper_limit>-3.103</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment</title>
        <description>Change from baseline in systolic blood pressure and diastolic blood pressure was assessed.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure who and had both baseline and post-baseline blood pressure measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment</title>
          <description>Change from baseline in systolic blood pressure and diastolic blood pressure was assessed.</description>
          <population>On-treatment analysis set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure who and had both baseline and post-baseline blood pressure measurements.</population>
          <units>Millimeter of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1398"/>
                <count group_id="O2" value="1415"/>
                <count group_id="O3" value="1388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP(Change at end of treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="0.377"/>
                    <measurement group_id="O2" value="-4.91" spread="0.375"/>
                    <measurement group_id="O3" value="-6.49" spread="0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP (Change at end of treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" spread="0.223"/>
                    <measurement group_id="O2" value="-3.70" spread="0.221"/>
                    <measurement group_id="O3" value="-4.51" spread="0.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (Systolic blood pressure) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-2.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.532</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.998</ci_lower_limit>
            <ci_upper_limit>-1.914</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (Systolic blood pressure) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-4.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.534</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.579</ci_lower_limit>
            <ci_upper_limit>-3.484</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (Diastolic blood pressure) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.314</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.437</ci_lower_limit>
            <ci_upper_limit>-0.205</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (Diastolic blood pressure) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>-1.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.316</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.245</ci_lower_limit>
            <ci_upper_limit>-1.007</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides Levels at End-of-Treatment</title>
        <description>Change from baseline in triglycerides levels was assessed.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline lipid measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides Levels at End-of-Treatment</title>
          <description>Change from baseline in triglycerides levels was assessed.</description>
          <population>On-treatment set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline lipid measurements.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1325"/>
                <count group_id="O2" value="1371"/>
                <count group_id="O3" value="1321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.597"/>
                    <measurement group_id="O2" value="0.13" spread="1.679"/>
                    <measurement group_id="O3" value="0.09" spread="1.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hodges-Lehman Estimate</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hodges-Lehman Estimate</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment</title>
        <description>Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline lipid measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment</title>
          <description>Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed.</description>
          <population>On-treatment set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline lipid measurements.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1325"/>
                <count group_id="O2" value="1371"/>
                <count group_id="O3" value="1321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol (change at EOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.028"/>
                    <measurement group_id="O2" value="0.11" spread="0.027"/>
                    <measurement group_id="O3" value="0.16" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (change at EOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.006"/>
                    <measurement group_id="O2" value="0.04" spread="0.006"/>
                    <measurement group_id="O3" value="0.05" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C (change at EOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.022"/>
                    <measurement group_id="O2" value="0.04" spread="0.022"/>
                    <measurement group_id="O3" value="0.10" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (Cholesterol) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (Cholesterol) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.307</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (HDL-C)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (HDL-C) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (LDL-C) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis (LDL-C) Comparison for canagliflozin versus placebo is reported here.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment</title>
        <description>Change from baseline in LDL-C to HDL-C ratio was assessed.</description>
        <time_frame>Baseline and end of treatment (approximately 338 weeks)</time_frame>
        <population>On-treatment set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline lipid measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment</title>
          <description>Change from baseline in LDL-C to HDL-C ratio was assessed.</description>
          <population>On-treatment set included all randomized participants who received at least 1 dose of study drug. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and who had both baseline and post-baseline lipid measurements.</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1325"/>
                <count group_id="O2" value="1371"/>
                <count group_id="O3" value="1321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.021"/>
                    <measurement group_id="O2" value="-0.02" spread="0.021"/>
                    <measurement group_id="O3" value="0.00" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference of Least Square Mean</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 8 years</time_frame>
      <desc>On-treatment analysis set included all randomized participants who were treated and received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received one placebo capsule orally once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 100 mg</title>
          <description>Participants received one canagliflozin 100 milligram (mg) capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
        <group group_id="E3">
          <title>Canagliflozin 300 mg</title>
          <description>Participants received one canagliflozin 300 mg capsule once daily for the duration of the study or until early discontinuation from treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="584" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="601" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="606" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Microcytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Normochromic Normocytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pernicious Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Acute Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adams-Stokes Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anginal Equivalent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Aortic Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cor Pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coronary Artery Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coronary Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myocardial Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pericarditis Constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulseless Electrical Activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Restrictive Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sinus Node Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Developmental Hip Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vitello-Intestinal Duct Remnant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness Neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Empty Sella Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism Primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis Fugax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blindness Unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cataract Diabetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cataract Nuclear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cataract Subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dacryostenosis Acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Exophthalmos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Eyelid Ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lens Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Macular Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Macular Hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ocular Myasthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Open Angle Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Optic Ischaemic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Retinal Vascular Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Retinopathy Proliferative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ulcerative Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vitreous Floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abdominal Incarcerated Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bowel Movement Irregularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colitis Microscopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colon Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colonic Pseudo-Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dieulafoy's Vascular Malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diverticulum Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diverticulum Intestinal Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Erosive Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallstone Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastric Mucosal Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastric Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hernial Eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Incarcerated Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oesophageal Achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oesophageal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oesophageal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oesophageal Varices Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatic Pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatitis Necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tooth Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Varices Oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Application Site Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Complication Associated with Device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Facial Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ischaemic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Medical Device Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Perforated Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Strangulated Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vascular Stent Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vascular Stent Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic Liver Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholangitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Drug-Induced Liver Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallbladder Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallbladder Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallbladder Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallbladder Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatorenal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Non-Alcoholic Steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Portal Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Cholecystectomy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abdominal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Biliary Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Burn Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Campylobacter Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cellulitis Gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cellulitis Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholecystitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colon Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Enterococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Eye Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Eye Infection Fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Groin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haematoma Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Helicobacter Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hiv Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Infected Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Infected Dermal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Infective Exacerbation of Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Klebsiella Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Medical Device Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Meningitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Necrotising Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Nosocomial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oesophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteomyelitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pathogen Resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pelvic Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Penile Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Perineal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Perinephric Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Plasmodium Vivax Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumonia Influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Procedural Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Postoperative Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pseudomonal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Psoas Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Staphylococcal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Staphylococcal Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Streptococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Streptococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Streptococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Superinfection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Testicular Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Typhoid Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vestibular Neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Viral Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vulval Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Wound Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Acetabulum Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anaesthetic Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arterial Bypass Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arterial Bypass Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bone Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Brain Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dural Tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Foreign Body in Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fracture Displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Heat Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Meniscus Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Muscle Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Concussion Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Procedural Bile Leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Postoperative Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Postoperative Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Postoperative Thoracic Procedure Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Procedural Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Procedural Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skull Fractured Base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Cord Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sternal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Stomal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Subcutaneous Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Subdural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tendon Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Traumatic Intracranial Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Retention Postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vascular Graft Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Wound Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Glucose Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Pressure Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Pressure Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cardiac Stress Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Catheterisation Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Clostridium Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Electrocardiogram St Segment Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Electrocardiogram St-T Segment Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Exercise Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Liver Function Test Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Precancerous Cells Present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyperosmolar Hyperglycaemic State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lactic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metabolic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metabolic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vitamin B12 Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Claw Toe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ankylosing Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bone Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bone Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dupuytren's Contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gouty Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gouty Tophus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Juvenile Idiopathic Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lupus-Like Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Muscle Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neuropathic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Polymyalgia Rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Senile Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Synovial Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tendon Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vertebral Foraminal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma Gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of Colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adenolymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adenosquamous Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adrenal Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Appendix Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm of Bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm of Prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Benign Peritoneal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bile Duct Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Cancer Stage 0, with Cancer in Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Breast Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Breast Cancer Stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bronchial Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bronchial Neoplasm Benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carcinoid Tumour Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carcinoid Tumour of the Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carotid Body Tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chondrosarcoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Myelomonocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Clear Cell Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colon Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colon Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colon Cancer Stage Iii</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Endometrial Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallbladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gallbladder Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Tract Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Head and Neck Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatocellular Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hodgkin's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Invasive Ductal Breast Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Kidney Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Large Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Large Intestine Benign Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Laryngeal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lentigo Maligna</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Squamous Cell Carcinoma Stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lymphocytic Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma in Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Melanocytic Naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastases to Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastases to Lymph Nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastases to Peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastases to Small Intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastatic Carcinoid Tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastatic Carcinoma of the Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastatic Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Metastatic Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Monoclonal Gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myeloproliferative Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Carcinoma of the Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer Stage Iv</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oesophageal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Papillary Serous Endometrial Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Paraneoplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Parathyroid Tumour Benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Penile Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostatic Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectal Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectal Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectosigmoid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Cancer Stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma Stage Ii</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sarcoma Uterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of the Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of the Tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Superficial Spreading Melanoma Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Testicular Seminoma (Pure)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Throat Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tonsil Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Transitional Cell Cancer of the Renal Pelvis and Ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Uterine Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Amyotrophic Lateral Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Basal Ganglia Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Basilar Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Brain Stem Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Brain Stem Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carotid Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carotid Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cerebellar Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cerebellar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cerebral Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cervicobrachial Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cubital Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Hyperosmolar Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Facial Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Facial Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Generalised Tonic-Clonic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyponatraemic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intercostal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intracranial Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lacunar Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lumbosacral Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Mental Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Motor Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myasthenia Gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Orthostatic Intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Paralysis Recurrent Laryngeal Nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Petit Mal Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Post Herpetic Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Reversible Cerebral Vasoconstriction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Serotonin Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Trigeminal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vertigo CNS Origin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vith Nerve Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vocal Cord Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Device Damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Delirium Tremens</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hallucination, Visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Schizoaffective Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vascular Cognitive Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Neck Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bladder Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Calculus Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Papillary Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Stress Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Terminal Dribbling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urethral Meatus Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Endometrial Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Epididymal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Genital Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Orchitis Noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pelvic Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostatic Calcification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Uterovaginal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vaginal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diaphragmatic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Idiopathic Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Laryngeal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Organising Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pulmonary Vein Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sinus Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Guttate Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypersensitivity Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Keloid Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lichen Planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Necrobiosis Lipoidica Diabeticorum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia Prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fracture Treatment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastric Bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hip Arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Incisional Hernia Repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arterial Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Pressure Inadequately Controlled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dry Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypertensive Emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Iliac Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Leriche Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neurogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Subclavian Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1137" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="1146" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1167" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Steatosis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Genital Infection Fungal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="203" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Mycotic Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="210" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="149" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="1441"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1441"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="1441"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Leader</name_or_title>
      <organization>Janssen- Cilag International NV</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

